Navellier & Associates Inc Exelixis, Inc. Transaction History
Navellier & Associates Inc
- $664 Million
- Q1 2025
A detailed history of Navellier & Associates Inc transactions in Exelixis, Inc. stock. As of the latest transaction made, Navellier & Associates Inc holds 145,058 shares of EXEL stock, worth $6.19 Million. This represents 0.81% of its overall portfolio holdings.
Number of Shares
145,058
Previous 31,179
365.24%
Holding current value
$6.19 Million
Previous $1.04 Million
415.9%
% of portfolio
0.81%
Previous 0.13%
Shares
7 transactions
Others Institutions Holding EXEL
# of Institutions
613Shares Held
257MCall Options Held
1.57MPut Options Held
730K-
Black Rock Inc. New York, NY33.5MShares$1.43 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA28.7MShares$1.22 Billion0.02% of portfolio
-
Farallon Capital Management LLC San Francisco, CA22.5MShares$962 Million4.78% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny14.8MShares$633 Million0.88% of portfolio
-
State Street Corp Boston, MA11.8MShares$503 Million0.02% of portfolio
About EXELIXIS, INC.
- Ticker EXEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 321,832,000
- Market Cap $13.7B
- Description
- Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...